AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
5min chapter
Freely Filtered 057: NephMadness 2023 TMA
Freely Filtered, a NephJC Podcast
Is Avocopan an Oral C5 Inhibitor?
For factor B and C3, I am particularly excited about them for C3G because they are targeting more proximal in the complement pathway. And then the Avocopan, which we're seeing approved for Incavascularitis, it's an oral C5 inhibitor. Do folks think about that as like a future maintenance therapy that's easier than coming in for IV echolizumab? Or I know that's super off label and no one should be doing that, but right.
00:00
Transcript
Episode notes
Get the Snipd
podcast app
Unlock the knowledge in podcasts with the podcast player of the future.
AI-powered
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode
Save any
moment
Hear something you like? Tap your headphones to save it with AI-generated key takeaways
Share
& Export
Send highlights to Twitter, WhatsApp or export them to Notion, Readwise & more
AI-powered
podcast player
Listen to all your favourite podcasts with AI-powered features
Discover
highlights
Listen to the best highlights from the podcasts you love and dive into the full episode